Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Immune checkpoint inhibitor (ICI) therapy has been established for patients with advanced urothelial cancer (UC). The necessity of overcoming resistance to ICIs and identifying a predictive factor for the same has been highlighted, such as the assessment of combination therapy with other targeted drugs and the characterization of molecular signatures in the tumor microenvironment. Recently, we reported that low hemoglobin (Hb) levels and a high platelet-to-lymphocyte ratio (PLR) were significantly associated with overall survival in patients with UC who did not benefit from pembrolizumab treatment. In the present study, we identified a possible link between these unfavorable prognostic indicators and PDGF-DD-induced STAT3 activation in UC. Overlapping patients between the high STAT3- or phosphorylated STAT3-positive score group (as assessed by immunohistochemistry) and low Hb levels or high PLR group (as assessed by blood tests) showed significantly worse outcomes after pembrolizumab treatment. Additionally, using the bladder cancer JMSU1 cell line, we demonstrated a possible positive regulatory loop between autocrine/paracrine PDGF-DD and STAT3 signaling. Therefore, we suggest that STAT3 inhibition and PDGF-DD detection in the tumor microenvironment might represent a potential therapeutic strategy to overcome resistance to pembrolizumab. Moreover, this can help identify patients with UC who could benefit from combination treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:676 |
|---|---|
| Enthalten in: |
Biochemical and biophysical research communications - 676(2023) vom: 08. Okt., Seite 165-170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ando, Kiyohiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder cancer |
|---|
| Anmerkungen: |
Date Revised 01.09.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.bbrc.2023.07.054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360170811 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360170811 | ||
| 003 | DE-627 | ||
| 005 | 20231226082437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbrc.2023.07.054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360170811 | ||
| 035 | |a (NLM)37517219 | ||
| 035 | |a (PII)S0006-291X(23)00920-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ando, Kiyohiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Immune checkpoint inhibitor (ICI) therapy has been established for patients with advanced urothelial cancer (UC). The necessity of overcoming resistance to ICIs and identifying a predictive factor for the same has been highlighted, such as the assessment of combination therapy with other targeted drugs and the characterization of molecular signatures in the tumor microenvironment. Recently, we reported that low hemoglobin (Hb) levels and a high platelet-to-lymphocyte ratio (PLR) were significantly associated with overall survival in patients with UC who did not benefit from pembrolizumab treatment. In the present study, we identified a possible link between these unfavorable prognostic indicators and PDGF-DD-induced STAT3 activation in UC. Overlapping patients between the high STAT3- or phosphorylated STAT3-positive score group (as assessed by immunohistochemistry) and low Hb levels or high PLR group (as assessed by blood tests) showed significantly worse outcomes after pembrolizumab treatment. Additionally, using the bladder cancer JMSU1 cell line, we demonstrated a possible positive regulatory loop between autocrine/paracrine PDGF-DD and STAT3 signaling. Therefore, we suggest that STAT3 inhibition and PDGF-DD detection in the tumor microenvironment might represent a potential therapeutic strategy to overcome resistance to pembrolizumab. Moreover, this can help identify patients with UC who could benefit from combination treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a PDGFD | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Platelet-to-lymphocyte ratio | |
| 650 | 4 | |a STAT3 | |
| 650 | 4 | |a Urothelial cancer | |
| 700 | 1 | |a Kurashina, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Motoi, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Iizuka, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Riko |e verfasserin |4 aut | |
| 700 | 1 | |a Mitani, Kouki |e verfasserin |4 aut | |
| 700 | 1 | |a Takenobu, Hisanori |e verfasserin |4 aut | |
| 700 | 1 | |a Haruta, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Onuki, Ritsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Yoh |e verfasserin |4 aut | |
| 700 | 1 | |a Kamijo, Takehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kageyama, Yukio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical and biophysical research communications |d 1960 |g 676(2023) vom: 08. Okt., Seite 165-170 |w (DE-627)NLM000000035 |x 1090-2104 |7 nnns |
| 773 | 1 | 8 | |g volume:676 |g year:2023 |g day:08 |g month:10 |g pages:165-170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbrc.2023.07.054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 676 |j 2023 |b 08 |c 10 |h 165-170 | ||